Company intelligence / Profile preview

Forty51 Ventures

Ownership: Private
Development stage: Other

Overview

Forty51 Ventures is an active Swiss-based venture capital and venture creation firm focused on building and investing in early-stage European biotech startups with clear paths to clinical development. They act as founding or first institutional investors for new ventures targeting significant unmet needs in life sciences. Their investments include seed funding for innovative therapeutics such as those developed by Allegria Therapeutics targeting allergies and mast cell-mediated diseases.

Therapeutic areas: Immunology
Modalities: Small moleculesBiologics
Industry: Investors

Beyond the preview

Go deeper on Forty51 Ventures.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Forty51 Ventures.

Explore the full profile